β受体阻滞剂在高血压应用中的专家共识
|
摘要
<正>β肾上腺素受体阻滞剂(以下简称β受体阻滞剂)自20世纪60年代以来已广泛用于防治心血管疾病,在高血压、冠心病、心力衰竭、心律失常及心肌病等的治疗中发挥着极其重要的作用~([1,2])。β受体阻滞剂是治疗高血压的五大类药物之一,疗效肯定。但自2005年起,因受到某些荟萃分析~([3])和英国修改高血压指南~([4])的影响,β受体阻滞剂的临床价
引文
[1]López-Sendón J,Swedberg K,McMurray J,et al.Expert conse nsus document on beta-adrenergic receptor blockers[J].Eur Heart J,2004,25(15):1341-1362.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J].中华心血管病杂志,2009,37(3):195-209.
[3]Lindholm LH,Carlberg B,Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension?Ameta-analysis[J].Lancet,2005,366(9496):1545-1553.
[4]Sever P.New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society[J].J Renin Angiotensin Aldosterone Syst,2006,7(2):61-63.
[5]中国高血压防治指南修订委员会.中国高血压防治指南(2010)[J].中国医学前沿杂志(电子版),2011,3(5):42-93.
[6]中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[7]Wang Z,Wang X,Chen Z,et al.Hypertension control in comm unity health centers across China:analysis of antihy pertensive drug treatment patterns[J].Am J Hypertens,2014,27(2):252-259.
[8]贾贡献,余金明,林凡礼,等.中国二级以上医院门诊初次诊断为高血压患者用药调查[J].中华高血压杂志,2013,21(9):743-747
[9]Wang Z,Chen Z,Zhang L,et al.Status of hypertension in China:results from the China Hypertension Survey,2012-2015[J].Circulation,2018,137(22):2344-2356.
[10]聂静雨,张林峰,陈祚,等.社区人群中高血压患者的用药情况分析[J].中华高血压杂志,2017,25(10):956-960.
[11]Lu J,Lu Y,Wang X,et al.Prevalence,awareness,treatment,and control of hypertension in China:data from 1.7 million adults in a population-based screening study(China PEACE Million Persons Project)[J].Lancet,2017,390(10112):2549-2558.
[12]Frishman WH.Beta-adrenergic receptor blockers in hyperte nsion:alive and well[J].Prog Cardiovasc Dis,2016,59(3):247-252.
[13]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESCGuidelines for the management of arterial hypertension:the Task Force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].J Hypertens,2013,31(7):1281-1357.
[14]Materson BJ,Reda DJ,Cushman WC.Department of Veterans Affairs single-drug therapy of hypertension study.Revised figures and new data.Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].Am J Hype rtens,1995,8(2):189-192.
[15]Law MR,Wald NJ,Morris JK,et al.Value of low dose combination treatment with blood pressure lowering drugs:analysis of354 randomised trials[J].BMJ,2003,326(7404):1427.
[16]Dickerson JE,Hingorani AD,Ashby MJ,et al.Optimisation of antihypertensive treatment by crossover rotation of four major classes[J].Lancet,1999,353(9169):2008-2013.
[17]Suonsyrj?T,Hannila-Handelberg T,Paavonen KJ,et al.Laboratory tests as predictors of the antihypertensive effects of amlodipine,bisoprolol,hydrochlorothiazide and losartan in men:results from the randomized,double-blind,crossover GENRES Study[J].J Hypertens,2008,26(6):1250-1256.
[18]White WB,Krishnan S,Giacco S,et al.Effects of metoprolol succinate extended release vs.amlodipine besylate on the blood pressure,heart rate,and the rate-pressure product in patients with hypertension[J].J Am Soc Hypertens,2008,2(5):378-384.
[19]郭冀珍,邵剑华,潘其兴,等.卡维地洛与拉贝洛尔治疗轻、中度高血压病399例的比较[J].中国新药与临床杂志,2000,19(2):81-84.
[20]刘国树,李鸣凤,石湘芸,等.三种国产降压药治疗高血压的多中心研究[J].中华内科杂志,2002,41(7):450-452.
[21]姜红,谢晋湘,刘力生,等.卡维地洛片治疗轻、中度原发性高血压的临床疗效--多中心随机、单盲、平行对照研究[J].中国医药导刊,2002,4(5):368-370.
[22]临床治疗协作组.比索洛尔与美托洛尔治疗高血压病疗效的对比研究[J].高血压杂志,2003,11(4):340-344.
[23]赵秀丽,胡大一,孙宁玲,等.卡维地洛与美托洛尔治疗原发性轻中度高血压的多中心临床研究[J].高血压杂志,2006,14(4):314-316.
[24]党爱民,刘国仗,蔡迺绳.盐酸阿罗洛尔对中青年高血压的降压疗效[J].中华高血压杂志,2011,19(2):163-166.
[25]荆珊,陈源源,孙宁玲,等.盐酸奈必洛尔片治疗轻中度原发性高血压有效性及安全性[J].中国临床药理学杂志,2013,29(2):83-85.
[26]Dahlof B,Lindholm LH,Hansson L,et al.Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension(STOP-Hypertension)[J].Lancet,1991,338(8778):1281-1285.
[27]Medical Research Council Working Party.MRC trial of treatment of mild hypertension:principal results[J].Br Med J(Clin Res Ed),1985,291(6488):97-104.
[28]The IPPPSH Collaborative Group.Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol:the International Prospective Primary Prevention Study in Hypertension(IPPPSH)[J].J Hypertens,1985,3(4):379-392.
[29]MRC Working Party.Medical Research Council trial of treatment of hypertension in older adults:principal results[J].BMJ,1992,304(6824):405-412.
[30]Wikstrand J,Warnold I,Olsson G,et al.Primary prevention with metoprolol in patients with hypertension:mortality results from the MAPHY Study[J].JAMA,1988,259(13):1976-1982.
[31]Hansson L,Linholm LH,Ekbom T,et al.Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study[J].Lancet,1999,354(9192):1751-1756.
[32]Hansson L,Lindholm LH,Niskanen L,et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hyp ertension:the Captopril Prevention Project(CAPPP)randomised trial[J].Lancet,1999,353(9153):611-616.
[33]Hansson L,Hedner T,Lund-Johansen P,et al.Randomised trial of effects of calcium antagonists compared with diuretics andβ-blockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem(NORDIL)study[J].Lancet,2000,356(9227):359-365.
[34]Dahl?f B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003.
[35]Dahl?f B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomised controlled trial[J].Lancet,2005,366(9489):895-906.
[36]Khan N,McAlister FA.Re-examining the efficacy ofβ-blockers for the treatment of hypertension:a meta-analysis[J].CMAJ,2006,174(12):1737-1742.
[37]Law MR,Morris JK,Wald NJ.Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J].BMJ,2009,338:b1665.
[38]Thomopoulos C,Parati G,Zanchetti A.Effects of blood pressure lowering on outcome incidence in hypertension:4.Effects of various classes of antihypertensive drugs--overview and metaanalyses[J].J Hypertens,2015,33(2):195-211.
[39]Blood Pressure Lowering Treatment Trialists'Collaboration.Effects of different regimens to lower blood pressure on major cardi o vascular events in older and younger adults:meta-analysis of randomised trials[J].BMJ,2008,336(7653):1121-1123.
[40]Whelton PK,Carey RM,Aronow WS,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNAGuideline for the Prevention,Detection,Evaluation,and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Hypertension,2018,71(6):e13-e115.
[41]National Institute for Health and Clinical Excellence(NICE).Hypertension in adults:diagnosis and management[M/OL].(2016-11)[2018-11-26].http://www.nice.org.uk/guidance/CG127.
[42]Shimamoto K,Ando K,Fujita T,et al.The Japanese Society of Hypertension Guidelines for the Management of Hypertension(JSH 2014)[J].Hypertens Res,2014,37(4):253-390.
[43]Williams B,Mancia G,Spiering W,et al.2018 ESC/ESHGuidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.
[44]Nerenberg KA,Zarnke KB,Leung AA,et al.Hypertension Canada's 2018 Guidelines for Diagnosis,Risk Assessment,Prevention,and Treatment of Hypertension in Adults and Children[J].Can J Cardiol,2018,34(5):506-525.
[45]V?gele A,Johansson T,Renom-Guiteras A,et al.Effectiveness and safety of beta blockers in the management of hypertension in older adults:a systematic review to help reduce inappropriate prescribing[J].BMC Geriatr,2017,17(Suppl 1):224.
[46]Rosendorff C,Black HR,MD,Cannon CP,et al.Treatment of hypertension in the prevention and management of ischemic heart disease:a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention[J].Circulation,2007,115(21):2761-2788.
[47]施仲伟.阿替洛尔的心脏保护作用缺乏证据[J].中华医学杂志,2005,85(13):928-930.
[48]Zhang Y,Sun N,Jiang L,et al.Comparative efficacy ofβ-blockers on mortality and cardiovascular outcomes in patients with hypertension:a systematic review and network metaanalysis[J].J Am Soc Hypertens,2017,11(7):394-401.
[49]Williams B,Lacy PS,Thom SM,et al.Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes:principal results of the Conduit Artery Function Evaluation(CAFE)study[J].Circulation,2006,113(9):1213-1225.
[50]Freemantle N,Cleland J,Young P,et al.beta Blockade after myocardial infarction:systematic review and meta regression analysis[J].BMJ,1999,318(7200):1730-1737.
[51]CIBIS-ⅡInvestigators and Committees.The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBISⅡ):a randomized trial[J].Lancet,1999,353(9146):9-13.
[52]MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized Interv ention Trial in Congestive Heart Failure(MERIT-HF)[J].Lancet,1999,353(9169):2001-2007.
[53]Packer M,Coats AJ,Fowler MB,et al.Effect of carvedilol on survival in severe chronic heart failure[J].N Engl J Med,2001,344(22):1651-1658.
[54]Dargie HJ.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial[J].Lancet,2001,357(9266):1385-1390.
[55]Wu H,Zhang Y,Huang J,et al.Clinical trial of arotinolol in the treatment of hypertensionL dippers vs.Nondippers[J].Hypertens Res,2001,24(5):605-610.
[56]Palatini P,Benetos A,Grassi G,et al.Identification and management of the hypertensive patient with elevated heart rate:statement of a European Society of Hypertension Cons ensus Meeting[J].J Hypertens,2006,24(4):603-610.
[57]Palatini P,Roseib EA,Casiglia E,et al.Management of the hypertensive patient with elevated heart rate:Statement of the Second Consensus Conference endorsed by the European Society of Hypertension[J].J Hypertens,2016,34(5):813-821.
[58]施仲伟,冯颖青,林金秀,等.高血压患者心率管理中国专家共识[J].中国医学前沿杂志(电子版),2017,9(8):29-36.
[59]孙宁玲,霍勇,黄峻.中国高血压患者心率现状调查[J].中华高血压杂志,2015,23(10):934-939.
[60]Grassi G,Vailati S,Bertinieri G,et al.Heart rate as marker of sympathetic activity[J].J Hypertens,1988,16(11):1635-1639.
[61]Bristow MR.beta-adrenergic receptor blockade in chronic heart failure[J].Circulation,2000,101(5):558-569.
[62]Gottlieb SS,McCarter RJ,Vogel RA.Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction[J].N Engl J Med,1998,339(8):489-497.
[63]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[64]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
[65]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[66]国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2018,10(6):1-130.
[67]Bavishi C,Chatterjee S,Ather S,et al.Beta-blockers in heart failure with preserved ejection fraction:a meta-analysis[J].Heart Fail Rev,2015,20(2):193-201.
[68]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[69]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[70]Hiratzka LF,Bakris GL,Beckman JA,et al.2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,American Association for Thoracic Surgery,American College of Radiology,American Stroke Association,Society of Cardiovascular Anesthesiologists,Society for Cardiovascular Angiography and Interventions,Society of Interventional Radiology,Society of Thoracic Surgeons,and Society for Vascular Medicine[J].J Am Coll Cardiol,2010,55(14):e27-e129.
[71]中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期高血压疾病诊治指南(2015)[J].中华妇产科杂志,2015,50(10):721-728.
[72]Halpern DG,Weinberg CR,Pinnelas R,et al.Use of medication for cardiovascular disease during pregnancy:JACC state-ofthe-art review[J].J Am Coll Cardiol,2019,73(4):457-476.
[73]Au DH,Bryson CL,Fan VS,et al.Beta-blockers as singleagent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease[J].Am JMed,2004,117(12):925-931.
[74]Dransfield MT,Rowe SM,Johnson JE,et al.Use of beta blockers and the risk of death in hospitalised patients with acute exaerbations of COPD[J].Thorax,2008,63(4):301-305.
[75]Short PM,Lipworth SI,Elder DH,et al.Effect of beta blockers in treatment of chronic obstructive pulmonary disease:a retrospective cohort study[J].BMJ,2011,342:d2549.
[76]Lainscak M,Podbregar M,Kovacic D,et al.Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease:a randomized trial[J].Respir Med,2011,105(1):S44-S49.
[77]Bouri S,Shun-Shin MJ,Cole GD,et al.Meta-analysis of secure randomised controlled trials ofβ-blockade to prevent perioperative death in non-cardiac surgery[J].Heart,2014,100(6):456-464.
[78]中华医学会心血管病学分会非心脏手术患者围术期β受体阻滞剂应用专家组.非心脏手术患者围术期β受体阻滞剂应用中国专家建议[J].中华心血管病杂志,2014,42(11):895-897.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J].中华心血管病杂志,2009,37(3):195-209.
[3]Lindholm LH,Carlberg B,Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension?Ameta-analysis[J].Lancet,2005,366(9496):1545-1553.
[4]Sever P.New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society[J].J Renin Angiotensin Aldosterone Syst,2006,7(2):61-63.
[5]中国高血压防治指南修订委员会.中国高血压防治指南(2010)[J].中国医学前沿杂志(电子版),2011,3(5):42-93.
[6]中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[7]Wang Z,Wang X,Chen Z,et al.Hypertension control in comm unity health centers across China:analysis of antihy pertensive drug treatment patterns[J].Am J Hypertens,2014,27(2):252-259.
[8]贾贡献,余金明,林凡礼,等.中国二级以上医院门诊初次诊断为高血压患者用药调查[J].中华高血压杂志,2013,21(9):743-747
[9]Wang Z,Chen Z,Zhang L,et al.Status of hypertension in China:results from the China Hypertension Survey,2012-2015[J].Circulation,2018,137(22):2344-2356.
[10]聂静雨,张林峰,陈祚,等.社区人群中高血压患者的用药情况分析[J].中华高血压杂志,2017,25(10):956-960.
[11]Lu J,Lu Y,Wang X,et al.Prevalence,awareness,treatment,and control of hypertension in China:data from 1.7 million adults in a population-based screening study(China PEACE Million Persons Project)[J].Lancet,2017,390(10112):2549-2558.
[12]Frishman WH.Beta-adrenergic receptor blockers in hyperte nsion:alive and well[J].Prog Cardiovasc Dis,2016,59(3):247-252.
[13]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESCGuidelines for the management of arterial hypertension:the Task Force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].J Hypertens,2013,31(7):1281-1357.
[14]Materson BJ,Reda DJ,Cushman WC.Department of Veterans Affairs single-drug therapy of hypertension study.Revised figures and new data.Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].Am J Hype rtens,1995,8(2):189-192.
[15]Law MR,Wald NJ,Morris JK,et al.Value of low dose combination treatment with blood pressure lowering drugs:analysis of354 randomised trials[J].BMJ,2003,326(7404):1427.
[16]Dickerson JE,Hingorani AD,Ashby MJ,et al.Optimisation of antihypertensive treatment by crossover rotation of four major classes[J].Lancet,1999,353(9169):2008-2013.
[17]Suonsyrj?T,Hannila-Handelberg T,Paavonen KJ,et al.Laboratory tests as predictors of the antihypertensive effects of amlodipine,bisoprolol,hydrochlorothiazide and losartan in men:results from the randomized,double-blind,crossover GENRES Study[J].J Hypertens,2008,26(6):1250-1256.
[18]White WB,Krishnan S,Giacco S,et al.Effects of metoprolol succinate extended release vs.amlodipine besylate on the blood pressure,heart rate,and the rate-pressure product in patients with hypertension[J].J Am Soc Hypertens,2008,2(5):378-384.
[19]郭冀珍,邵剑华,潘其兴,等.卡维地洛与拉贝洛尔治疗轻、中度高血压病399例的比较[J].中国新药与临床杂志,2000,19(2):81-84.
[20]刘国树,李鸣凤,石湘芸,等.三种国产降压药治疗高血压的多中心研究[J].中华内科杂志,2002,41(7):450-452.
[21]姜红,谢晋湘,刘力生,等.卡维地洛片治疗轻、中度原发性高血压的临床疗效--多中心随机、单盲、平行对照研究[J].中国医药导刊,2002,4(5):368-370.
[22]临床治疗协作组.比索洛尔与美托洛尔治疗高血压病疗效的对比研究[J].高血压杂志,2003,11(4):340-344.
[23]赵秀丽,胡大一,孙宁玲,等.卡维地洛与美托洛尔治疗原发性轻中度高血压的多中心临床研究[J].高血压杂志,2006,14(4):314-316.
[24]党爱民,刘国仗,蔡迺绳.盐酸阿罗洛尔对中青年高血压的降压疗效[J].中华高血压杂志,2011,19(2):163-166.
[25]荆珊,陈源源,孙宁玲,等.盐酸奈必洛尔片治疗轻中度原发性高血压有效性及安全性[J].中国临床药理学杂志,2013,29(2):83-85.
[26]Dahlof B,Lindholm LH,Hansson L,et al.Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension(STOP-Hypertension)[J].Lancet,1991,338(8778):1281-1285.
[27]Medical Research Council Working Party.MRC trial of treatment of mild hypertension:principal results[J].Br Med J(Clin Res Ed),1985,291(6488):97-104.
[28]The IPPPSH Collaborative Group.Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol:the International Prospective Primary Prevention Study in Hypertension(IPPPSH)[J].J Hypertens,1985,3(4):379-392.
[29]MRC Working Party.Medical Research Council trial of treatment of hypertension in older adults:principal results[J].BMJ,1992,304(6824):405-412.
[30]Wikstrand J,Warnold I,Olsson G,et al.Primary prevention with metoprolol in patients with hypertension:mortality results from the MAPHY Study[J].JAMA,1988,259(13):1976-1982.
[31]Hansson L,Linholm LH,Ekbom T,et al.Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study[J].Lancet,1999,354(9192):1751-1756.
[32]Hansson L,Lindholm LH,Niskanen L,et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hyp ertension:the Captopril Prevention Project(CAPPP)randomised trial[J].Lancet,1999,353(9153):611-616.
[33]Hansson L,Hedner T,Lund-Johansen P,et al.Randomised trial of effects of calcium antagonists compared with diuretics andβ-blockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem(NORDIL)study[J].Lancet,2000,356(9227):359-365.
[34]Dahl?f B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003.
[35]Dahl?f B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomised controlled trial[J].Lancet,2005,366(9489):895-906.
[36]Khan N,McAlister FA.Re-examining the efficacy ofβ-blockers for the treatment of hypertension:a meta-analysis[J].CMAJ,2006,174(12):1737-1742.
[37]Law MR,Morris JK,Wald NJ.Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J].BMJ,2009,338:b1665.
[38]Thomopoulos C,Parati G,Zanchetti A.Effects of blood pressure lowering on outcome incidence in hypertension:4.Effects of various classes of antihypertensive drugs--overview and metaanalyses[J].J Hypertens,2015,33(2):195-211.
[39]Blood Pressure Lowering Treatment Trialists'Collaboration.Effects of different regimens to lower blood pressure on major cardi o vascular events in older and younger adults:meta-analysis of randomised trials[J].BMJ,2008,336(7653):1121-1123.
[40]Whelton PK,Carey RM,Aronow WS,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNAGuideline for the Prevention,Detection,Evaluation,and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Hypertension,2018,71(6):e13-e115.
[41]National Institute for Health and Clinical Excellence(NICE).Hypertension in adults:diagnosis and management[M/OL].(2016-11)[2018-11-26].http://www.nice.org.uk/guidance/CG127.
[42]Shimamoto K,Ando K,Fujita T,et al.The Japanese Society of Hypertension Guidelines for the Management of Hypertension(JSH 2014)[J].Hypertens Res,2014,37(4):253-390.
[43]Williams B,Mancia G,Spiering W,et al.2018 ESC/ESHGuidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.
[44]Nerenberg KA,Zarnke KB,Leung AA,et al.Hypertension Canada's 2018 Guidelines for Diagnosis,Risk Assessment,Prevention,and Treatment of Hypertension in Adults and Children[J].Can J Cardiol,2018,34(5):506-525.
[45]V?gele A,Johansson T,Renom-Guiteras A,et al.Effectiveness and safety of beta blockers in the management of hypertension in older adults:a systematic review to help reduce inappropriate prescribing[J].BMC Geriatr,2017,17(Suppl 1):224.
[46]Rosendorff C,Black HR,MD,Cannon CP,et al.Treatment of hypertension in the prevention and management of ischemic heart disease:a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention[J].Circulation,2007,115(21):2761-2788.
[47]施仲伟.阿替洛尔的心脏保护作用缺乏证据[J].中华医学杂志,2005,85(13):928-930.
[48]Zhang Y,Sun N,Jiang L,et al.Comparative efficacy ofβ-blockers on mortality and cardiovascular outcomes in patients with hypertension:a systematic review and network metaanalysis[J].J Am Soc Hypertens,2017,11(7):394-401.
[49]Williams B,Lacy PS,Thom SM,et al.Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes:principal results of the Conduit Artery Function Evaluation(CAFE)study[J].Circulation,2006,113(9):1213-1225.
[50]Freemantle N,Cleland J,Young P,et al.beta Blockade after myocardial infarction:systematic review and meta regression analysis[J].BMJ,1999,318(7200):1730-1737.
[51]CIBIS-ⅡInvestigators and Committees.The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBISⅡ):a randomized trial[J].Lancet,1999,353(9146):9-13.
[52]MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized Interv ention Trial in Congestive Heart Failure(MERIT-HF)[J].Lancet,1999,353(9169):2001-2007.
[53]Packer M,Coats AJ,Fowler MB,et al.Effect of carvedilol on survival in severe chronic heart failure[J].N Engl J Med,2001,344(22):1651-1658.
[54]Dargie HJ.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial[J].Lancet,2001,357(9266):1385-1390.
[55]Wu H,Zhang Y,Huang J,et al.Clinical trial of arotinolol in the treatment of hypertensionL dippers vs.Nondippers[J].Hypertens Res,2001,24(5):605-610.
[56]Palatini P,Benetos A,Grassi G,et al.Identification and management of the hypertensive patient with elevated heart rate:statement of a European Society of Hypertension Cons ensus Meeting[J].J Hypertens,2006,24(4):603-610.
[57]Palatini P,Roseib EA,Casiglia E,et al.Management of the hypertensive patient with elevated heart rate:Statement of the Second Consensus Conference endorsed by the European Society of Hypertension[J].J Hypertens,2016,34(5):813-821.
[58]施仲伟,冯颖青,林金秀,等.高血压患者心率管理中国专家共识[J].中国医学前沿杂志(电子版),2017,9(8):29-36.
[59]孙宁玲,霍勇,黄峻.中国高血压患者心率现状调查[J].中华高血压杂志,2015,23(10):934-939.
[60]Grassi G,Vailati S,Bertinieri G,et al.Heart rate as marker of sympathetic activity[J].J Hypertens,1988,16(11):1635-1639.
[61]Bristow MR.beta-adrenergic receptor blockade in chronic heart failure[J].Circulation,2000,101(5):558-569.
[62]Gottlieb SS,McCarter RJ,Vogel RA.Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction[J].N Engl J Med,1998,339(8):489-497.
[63]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[64]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
[65]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[66]国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2018,10(6):1-130.
[67]Bavishi C,Chatterjee S,Ather S,et al.Beta-blockers in heart failure with preserved ejection fraction:a meta-analysis[J].Heart Fail Rev,2015,20(2):193-201.
[68]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[69]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[70]Hiratzka LF,Bakris GL,Beckman JA,et al.2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,American Association for Thoracic Surgery,American College of Radiology,American Stroke Association,Society of Cardiovascular Anesthesiologists,Society for Cardiovascular Angiography and Interventions,Society of Interventional Radiology,Society of Thoracic Surgeons,and Society for Vascular Medicine[J].J Am Coll Cardiol,2010,55(14):e27-e129.
[71]中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期高血压疾病诊治指南(2015)[J].中华妇产科杂志,2015,50(10):721-728.
[72]Halpern DG,Weinberg CR,Pinnelas R,et al.Use of medication for cardiovascular disease during pregnancy:JACC state-ofthe-art review[J].J Am Coll Cardiol,2019,73(4):457-476.
[73]Au DH,Bryson CL,Fan VS,et al.Beta-blockers as singleagent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease[J].Am JMed,2004,117(12):925-931.
[74]Dransfield MT,Rowe SM,Johnson JE,et al.Use of beta blockers and the risk of death in hospitalised patients with acute exaerbations of COPD[J].Thorax,2008,63(4):301-305.
[75]Short PM,Lipworth SI,Elder DH,et al.Effect of beta blockers in treatment of chronic obstructive pulmonary disease:a retrospective cohort study[J].BMJ,2011,342:d2549.
[76]Lainscak M,Podbregar M,Kovacic D,et al.Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease:a randomized trial[J].Respir Med,2011,105(1):S44-S49.
[77]Bouri S,Shun-Shin MJ,Cole GD,et al.Meta-analysis of secure randomised controlled trials ofβ-blockade to prevent perioperative death in non-cardiac surgery[J].Heart,2014,100(6):456-464.
[78]中华医学会心血管病学分会非心脏手术患者围术期β受体阻滞剂应用专家组.非心脏手术患者围术期β受体阻滞剂应用中国专家建议[J].中华心血管病杂志,2014,42(11):895-897.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |